Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/231313
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients |
Autor: | Cordero-Matía, Elisa CSIC ORCID; Bulnes-Ramos, Ángel CSIC; Aguilar Guisado, Manuela CSIC ORCID; González-Escribano, María Francisca CSIC ORCID; Olivas-Martínez, Israel CSIC; Torre-Cisneros, Julián; Gavaldà, Joan; Aydillo, T. A.; Moreno, Asunción; Montejo, Miguel; Fariñas, María del Carmen; Carratalà, Jordi; Muñoz, Patricia; Blanes, Marino; Fortún, Jesús; Suarez-Benjumea, Alejandro; López-Medrano, Francisco; Roca-Oporto, Cristina CSIC; Lara, Rosario; Pérez-Romero, Pilar CSIC ORCID | Palabras clave: | Cytomegalovirus Alloreactivity Donor specific antibodies Anti-human leukocyte antigen Organ rejection |
Fecha de publicación: | 6-oct-2020 | Editor: | Frontiers Media | Citación: | Frontiers in Immunology 11: 1917 (2020) | Resumen: | [Introduction] Our goal was to study whether influenza vaccination induced antibody mediated rejection in a large cohort of solid organ transplant recipients (SOTR). [Methods] Serum anti-Human Leukocyte Antigen (HLA) antibodies were determined using class I and class II antibody-coated latex beads (FlowPRATM Screening Test) by flow cytometry. Anti-HLA antibody specificity was determined using the single-antigen bead flow cytometry (SAFC) assay and assignation of donor specific antibodies (DSA) was performed by virtual-crossmatch. [Results] We studied a cohort of 490 SOTR that received an influenza vaccination from 2009 to 2013: 110 (22.4%) received the pandemic adjuvanted vaccine, 59 (12%) within the first 6 months post-transplantation, 185 (37.7%) more than 6 months after transplantation and 136 (27.7%) received two vaccination doses. Overall, no differences of anti-HLA antibodies were found after immunization in patients that received the adjuvanted vaccine, within the first 6 months post-transplantation, or based on the type of organ transplanted. However, the second immunization dose increased the percentage of patients positive for anti-HLA class I significantly compared with patients with one dose (14.6% vs. 3.8%; P = 0.003). Patients with pre-existing antibodies before vaccination (15.7% for anti-HLA class I and 15.9% for class II) did not increase reactivity after immunization. A group of 75 (14.4%) patients developed de novo anti-HLA antibodies, however, only 5 (1.02%) of them were DSA, and none experienced allograft rejection. Only two (0.4%) patients were diagnosed with graft rejection with favorable outcomes and neither of them developed DSA. [Conclusion] Our results suggest that influenza vaccination is not associated with graft rejection in this cohort of SOTR. |
Versión del editor: | http://doi.org/10.3389/fimmu.2020.01917 | URI: | http://hdl.handle.net/10261/231313 | DOI: | 10.3389/fimmu.2020.01917 | Identificadores: | doi: 10.3389/fimmu.2020.01917 e-issn: 1664-3224 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Influenza_ Vaccination.pdf | 724,59 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
11
checked on 10-abr-2024
SCOPUSTM
Citations
16
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
16
checked on 26-feb-2024
Page view(s)
97
checked on 23-abr-2024
Download(s)
92
checked on 23-abr-2024